Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
survivin UsiRNA-DiLA2
- Development stage
- Discontinued
- Lead developer
- Marina Biotech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intravesical
01
Overview
Survivin UsiRNA-DiLA2 is an experimental RNA interference (RNAi) therapeutic developed by MDRNA Inc. (later Marina Biotech). The drug consists of a "UsiRNA"—a small interfering RNA (siRNA) construct incorporating unlocked nucleobase analogs (UNA) to enhance stability and reduce off-target effects—designed to silence the expression of the survivin (BIRC5) gene. Survivin is an inhibitor of apoptosis (IAP) protein that is overexpressed in many malignancies, where it promotes cell survival and regulates mitosis. The UsiRNA is delivered using the proprietary Di-alkylated Amino Acid (DiLA2) liposomal platform, which facilitates systemic or local delivery to tumor tissues. Preclinical studies demonstrated significant knockdown of survivin mRNA and inhibition of tumor growth in models of bladder cancer and hepatocellular carcinoma.
- Other names
- Survivin UsiRNA-DiLA2 liposomes
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on survivin UsiRNA-DiLA2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on survivin UsiRNA-DiLA2.